General Electric announced Friday that its healthcare unit will acquire molecular diagnostics company Clarient in a deal worth approximately $580 million.
Infectious Diseases, Oncology, Immunology
This company is a specialty biopharmaceutical company that has established a drug development platform to actualize an orally administered, low-dose version of the drug interferon, which is a well characterized immune system modulator. Interferon serves as one of the most…
Genomics Researchers Have a Bone to Pick with Multiple Myeloma
Signal Genetics, a predictive genetic testing company focused on oncology, recently announced that it would work with pharmaceutical company Array BioPharma to advance both companies’ goals of finding biomarkers for myeloma patients.
The 1st Annual Miami Medical Investors Conference: November 12, 2010
LifeTech Capital invites you to their 1st Annual Miami Medical Investors Conference November 12th at the brand new JW Marriott Marquis Miami.
China Analyst Identifies 10 Pharma Stocks with Highest Growth Potential
China Analyst, a financial information website focused on U.S.-listed Chinese stocks, recently released its list of the top 10 pharmaceutical stocks with the highest upside.
A Unique Roadblock for Pfizer’s Osteoarthritis Drug
We’ve heard of drugs underperforming in clinical trials, but is it possible for a drug to over-perform?
Bone Fractures Expected to Contribute to Growth of Orthopedic Implant Market
Minnesota-based orthopedics startup Dgimed Ortho is seeking to raise $2 million for its bone-fracture system.
A Busy Week for Multiple Sclerosis News
It was good news for Novartis and bad news for Merck KGaA this week as regulators handed down their decisions on each company’s multiple sclerosis (MS) drug candidate.
